Intrommune Therapeutics Presents at Next Generation Food Allergy Drug Summit
July 22, 2021 16:57 ET
|
Intrommune Therapeutics
NEW YORK, July 22, 2021 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, a New York-based clinical stage biotechnology company developing a patient-friendly treatment platform for peanut and other food...
Intrommune Therapeutics to Present at BIO Digital 2021
June 17, 2021 09:11 ET
|
Intrommune Therapeutics
NEW YORK, June 17, 2021 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, a New York-based clinical stage biotechnology company developing a patient-friendly treatment platform for peanut and other food...
Zoom-In on Health Equity: AAFA Asks Congress to Tackle Racial Disparities in Asthma and Allergy
April 30, 2021 14:22 ET
|
Asthma and Allergy Foundation of America
Washington, D.C, April 30, 2021 (GLOBE NEWSWIRE) -- Each year, the Asthma and Allergy Foundation of America (AAFA) brings patient spokespeople and advocates from across the nation to Congress to...
AAFA Meets Asthma and Allergy Awareness Month with 31 DAYS OF ACTION
April 29, 2021 14:03 ET
|
Asthma and Allergy Foundation of America
Washington, D.C, April 29, 2021 (GLOBE NEWSWIRE) -- May is National Asthma and Allergy Awareness Month. This year the Asthma and Allergy Foundation of America (AAFA) is encouraging everyone to look...
AAFA Celebrates Massive Health Policy Change; Lawmakers Pass FASTER Act Making Sesame A Major Food Allergen
April 14, 2021 17:55 ET
|
Asthma and Allergy Foundation of America
Washington, D.C., April 14, 2021 (GLOBE NEWSWIRE) -- Today the House passed Act, S. 578/H.R.1202, otherwise known as the FASTER Act. It declares sesame the 9th major food allergen recognized by law...
Intrommune Therapeutics Names Chief Operating Officer
March 25, 2021 09:10 ET
|
Intrommune Therapeutics
NEW YORK, March 25, 2021 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, a New York-based, clinical stage biotechnology company developing a patient-friendly treatment platform for peanut and other...
Research Presentations at the 2021 Annual AAAAI Meeting Highlight Limitations of Current Food Allergy Treatments and Further Validates Intrommune Therapeutics’ Approach
March 12, 2021 09:30 ET
|
Intrommune Therapeutics
NEW YORK, March 12, 2021 (GLOBE NEWSWIRE) -- The clinical and scientific team of Intrommune Therapeutics, a New York-based clinical stage biotechnology company developing patient-friendly treatments...
Intrommune Therapeutics Publishes Peanut Allergy and Immunotherapy Report
February 23, 2021 12:00 ET
|
Intrommune Therapeutics
NEW YORK, Feb. 23, 2021 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, a New York-based clinical stage biotechnology company developing a patient-friendly immunotherapy platform for the treatment of...
Intrommune Receives IND Clearance From U.S. Food and Drug Administration for INT301
February 04, 2021 09:13 ET
|
Intrommune Therapeutics
NEW YORK, Feb. 04, 2021 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, a New York-based biotechnology company developing a patient-friendly treatment platform for peanut and other food allergies,...
Intrommune to Participate in BIO @ JPM During “J.P. Morgan Week 2021”
January 07, 2021 17:35 ET
|
Intrommune Therapeutics
NEW YORK, Jan. 07, 2021 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, a New York-based biotechnology company developing a patient-friendly treatment platform for peanut and other food allergies, will...